Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00135434 |
Recruitment Status
:
Completed
First Posted
: August 26, 2005
Last Update Posted
: April 8, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Atazanavir/Ritonavir/Lopinavir/ritonavir | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 25 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism |
Study Start Date : | September 2004 |
Actual Primary Completion Date : | June 2005 |
Actual Study Completion Date : | June 2005 |

- Insulin sensitivity by euglycemic hyperinsulinemic clamp method
- Insulin sensitivity by oral glucose tolerance
- Lipids and lipoproteins

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy volunteers

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00135434
United States, New Jersey | |
Clinical Pharmacology Unit, Bristol-Myers Squibb Company | |
Hamilton, New Jersey, United States, 08690 |
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Additional Information:
Responsible Party: | Study Director, Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00135434 History of Changes |
Other Study ID Numbers: |
AI424-130 |
First Posted: | August 26, 2005 Key Record Dates |
Last Update Posted: | April 8, 2011 |
Last Verified: | November 2009 |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Lopinavir |
Atazanavir Sulfate HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |